Bepridil is a potent calcium channel blocker/antagonist and class IV anti-arrhythmic agent once used to treat angina but is no longer on the market.

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

# Bepridil (Class IV antiarrhythmic, non-selective calcium/sodium/potassium channel blocker, withdrawn in many markets due torsades risk)
Single oral ascending dose first-in-human Phase 1 safety, hemodynamic and pharmacokinetic study of oral Bepridil in healthy normotensive volunteers
CTID: Not Applicable
Phase: Phase 1 SAD
Status: Completed
Date: 1974

---

Phase 1 multiple daily dosing crossover PK substudy evaluating food effect, age, mild hepatic/renal impairment on systemic exposure of Bepridil tablets
CTID: Not Applicable
Phase: Phase 1 MAD Substudy
Status: Completed
Date: 1975

---

Phase 1 intracardiac electrophysiology PD substudy measuring sinus node, AV node and ventricular repolarization effects in healthy subjects
CTID: Not Applicable
Phase: Phase 1 EP PD Substudy
Status: Completed
Date: 1976

---

Randomized double-blind placebo-controlled Phase 2 dose-ranging trial of oral Bepridil for chronic stable angina pectoris
CTID: Not Applicable
Phase: Phase 2
Status: Completed
Date: 1977

---

Multicenter double-blind active-controlled Phase 2 comparative trial: Bepridil vs Verapamil for effort-induced angina, assessing exercise tolerance and hemodynamic changes
CTID: Not Applicable
Phase: Phase 2 Comparative
Status: Completed
Date: 1978

---

Multinational double-blind placebo-controlled pivotal Phase 3 trial of Bepridil for refractory ventricular arrhythmias in patients with structural heart disease
CTID: Not Applicable
Phase: Phase 3 Pivotal
Status: Completed
Date: 1981

---

Open-label long-term Phase 3 extension safety study of chronic Bepridil maintenance therapy, monitoring QTc prolongation and torsades de pointes adverse events
CTID: Not Applicable
Phase: Phase 3 Extension
Status: Terminated early
Date: 1984

---

Phase 3 comparative head-to-head trial Bepridil vs Amiodarone for sustained ventricular tachycardia
CTID: Not Applicable
Phase: Phase 3 Comparative Antiarrhythmic
Status: Completed
Date: 1985

---

Post-marketing Phase 4 large-scale observational safety registry documenting dose-dependent QTc prolongation and sudden cardiac death signals leading to market restriction/withdrawal
CTID: Not Applicable
Phase: Phase 4 Post-Marketing Safety
Status: Completed
Date: 1992

---

Preclinical in vitro ion channel patch-clamp assay profiling multi-channel block: L-type Ca²⁺, Na⁺ late current, hERG K⁺ channel inhibitory activity
CTID: Not Applicable
Phase: Preclinical Biochemical Electrophysiology
Status: Completed
Date: 1972

---

In vivo canine myocardial ischemia preclinical efficacy study of intravenous Bepridil reducing infarct size and coronary vasodilation
CTID: Not Applicable
Phase: Preclinical Cardiovascular Efficacy
Status: Completed
Date: 1973

---

Chronic oral repeat-dose toxicology preclinical trial of Bepridil in dogs and rats characterizing cardiac repolarization toxicity and hepatic lipid accumulation
CTID: Not Applicable
Phase: Preclinical Toxicology
Status: Completed
Date: 1974

---

Radiolabeled [¹⁴C]-Bepridil whole-body ADME biodistribution preclinical study identifying extensive tissue accumulation and biliary excretion primary clearance route
CTID: Not Applicable
Phase: Preclinical ADME
Status: Completed
Date: 1975

---

Modern in vitro hERG risk comparison preclinical study benchmarking Bepridil QT liability against contemporary antianginal agents
CTID: Not Applicable
Phase: Preclinical Safety Pharmacology Follow-Up
Status: Completed
Date: 2010